Fortinet Inc vs Medpace Holdings Inc — how do they compare? Fortinet Inc trades at $192.77 (market cap $138.75B), while Medpace Holdings Inc trades at $616.5 (market cap $16.82B). The key difference: Fortinet Inc is far larger — about 8.2× Medpace Holdings Inc's market cap, and Medpace Holdings Inc is more actively traded (223,093 versus 2,956,908). Which is the better fit depends on your goals — on Pluang, investors hold Fortinet Inc for 72 Days and Medpace Holdings Inc for 14 Days on average.
| FTNT | MEDP | |
|---|---|---|
Market Cap | $138.75B | $16.82B |
Volume | 2,956,908 | 223,093 |
Sector | Technology | Health |
52-Week High | $191.27 | $630.19 |
52-Week Low | $75.23 | $393.42 |
Typical Hold Time | 72 Days | 14 Days |
Enterprise Value | $135.17B | $16.44B |
Signals from Pluang's Aura AI — not financial advice
FTNT trades at $189.28, down 1.04% on the day but near its 52-week high, with a bullish technical signal from moving averages. The company reported strong earnings beats in recent quarters, with Q3 2026 results pending. Revenue grew to $6.80B in 2025, supported by an 80.2% gross margin and robust cash flow from operations of $2.59B. Analyst sentiment is mixed, with 42% buy ratings but a consensus price target of $158.64 below the current price.
Outlook remains positive due to cybersecurity demand and AI-driven growth, but high valuation ratios (P/E of 66.82) pose risks. Competition and execution challenges could pressure margins. Institutional interest is strong, with recent position increases noted in SEC filings. The stock's momentum depends on continued earnings outperformance and market share gains in data center security.
MEDP trades at $604.25, up 0.22% today, with a neutral technical signal and strong fundamental performance. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results expected on October 21, 2026. Revenue grew to $2.53 billion in 2025, with a net income margin of 17.67% and robust ROE of 162.15%. Analyst consensus is a $620.44 price target, though institutional sentiment is mixed with recent CEO share sales.
Outlook remains positive given earnings momentum and projected 2026 revenue growth to $2.8 billion. Key risks include high valuation multiples and insider selling. The stock offers upside to consensus target but requires monitoring of Q3 earnings and competitive pressures in medical services.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Fortinet is a cybersecurity vendor that sells products, support, and services to small and midsize businesses, enterprises, and government entities. Its products include unified threat management appliances, firewalls, network security, and its security platform, Security Fabric. Services revenue is primarily from FortiGuard security subscriptions and FortiCare technical support. At the end of 2021, products were 38% of revenue and services were 62% of sales. The California-based company sells products worldwide.
Read more on FTNT →Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →